News Related to Severe Hypertriglyceridemia

Related coverage linked through entity extraction aliases.

Arrowhead Pharmaceuticals Reports Strong Long-Term Data for Plozasiran in Hypertriglyceridemia

Mar 29, 2026

Arrowhead Pharmaceuticals presented long-term data showing plozasiran achieved 83% median triglyceride reduction in severe hypertriglyceridemia patients with no acute pancreatitis events over two years. The RNA interference therapy demonstrated durable improvements in atherogenic lipoproteins and consistent safety profile. The company plans to complete Phase 3 studies by mid-2026 and submit for regulatory approval.

CRISPR Therapeutics Reports Wider-Than-Expected Q4 Loss, Sales Miss Estimates

Mar 28, 2026

CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.